keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvent

keyword
https://www.readbyqxmd.com/read/30325838/vascularized-tissue-reconstruction-in-previously-irradiated-sarcoma-defects
#1
Alain Joe Azzi, Sarah Zhou, Tyler Safran, Liqin Xu, Nayif Alnaif, Teanoosh Zadeh
INTRODUCTION: Radiation therapy (RT) is recommended for appropriately selected sarcoma patients to minimize the risk of local recurrence and to maximize outcomes of disease-free survival and function. The purpose of this study was to confirm the safety of vascularized tissue reconstruction in recently irradiated sarcoma defects. METHODS: A retrospective review of all patients treated by the senior author for sarcoma reconstruction from January 2005 to July 2017 was performed...
October 15, 2018: Annals of Plastic Surgery
https://www.readbyqxmd.com/read/30325753/immunotherapy-in-patients-with-early-stage-resectable-nonsmall-cell-lung-cancer
#2
Katrien Ghysen, Johan Vansteenkiste
PURPOSE OF REVIEW: 'Early-stage' nonsmall cell lung cancer (NSCLC) refers to stage I and stage II disease, and selected cases of stage IIIA disease where complete tumor resection is feasible. Surgery is the standard treatment for early NSCLC, but the overall 5-year survival remains below 50%. The addition of adjuvant cisplatin-based chemotherapy to surgery improved 5-year survival rates by 5-10%, but no significant therapeutic innovation has been established thereafter. We review recent and ongoing studies looking how immunotherapy may improve the outcome of these patients...
October 15, 2018: Current Opinion in Oncology
https://www.readbyqxmd.com/read/30325030/impact-of-neoadjuvant-radiation-on-margins-for-non-squamous-cell-carcinoma-sinonasal-malignancies
#3
Terence Fu, Christopher J Chin, Wei Xu, Jiahua Che, Shao Hui Huang, Eric Monteiro, Yazeed Alghonaim, Jolie Ringash, Ian J Witterick
OBJECTIVES/HYPOTHESIS: Treatment of non-squamous cell carcinoma sinonasal malignancies (NSCCSMs) typically involves surgery and radiotherapy (RT), but optimal sequencing remains controversial. STUDY DESIGN: Retrospective chart review. METHODS: Patients with NSCCSM treated with combined surgery and RT between 2000 and 2011 were identified. Margin control, overall survival, disease-free survival, local recurrence-free survival, and regional recurrence-free survival were compared between neoadjuvant and adjuvant RT groups...
October 16, 2018: Laryngoscope
https://www.readbyqxmd.com/read/30324992/prognostic-impact-of-the-2015-world-health-organisation-classification-of-lung-adenocarcinoma-a-study-in-departement-specialized-in-thoracic-pathology
#4
Mona Mlika, Imen Helal, Ali Mrabet, Faouzi El Mezni
BACKGROUND: The 2015 WHO classification of primary lung adenocarcinomas idendified not only new subtypes but also new prognostic groups. Solid and micropapillary adenocarcinomas are considered of bad prognosis, lepidici adenocarcinomas are considered of good prognosis and acinary and papillary ones are considered of intermediate prognosis. We aimed to assess the prognostic relevance of this classification through the experience of a specialized Department in Thoracic Oncology. METHODS: We described a survival study about 101 patients presenting primary adenocarcinomas diagnosed between 2008 and 2011...
January 2018: La Tunisie Médicale
https://www.readbyqxmd.com/read/30324476/aso-author-reflections-role-of-contrast-enhanced-spectral-mammography-in-the-assessment-of-residual-breast-cancer-after-neoadjuvant-systemic-therapy
#5
Talal Hilal, Bhavika K Patel
No abstract text is available yet for this article.
October 15, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/30324389/prospective-multimodal-imaging-assessment-of-locally-advanced-cervical-cancer-patients-administered-by-chemoradiation-followed-by-radical-surgery-the-price-study-2-role-of-conventional-and-dw-mri
#6
B Gui, M Miccò, A L Valentini, F Cambi, T Pasciuto, A Testa, R Autorino, G F Zannoni, V Rufini, M A Gambacorta, A Giordano, G Scambia, R Manfredi
OBJECTIVES: To assess the diagnostic performance of conventional and DW-MRI parameters in the detection of residual tumor in locally advanced cervical cancer (LACC) patients treated with neoadjuvant chemoradiotherapy (nCRT) and radical surgery METHODS: Between October 2010 and June 2014, 88 patients with histologically documented cervical cancer (FIGO stage IB2-IVA) were prospectively included in the study. Maximum tumor diameters (max TD), tumor volume (TV), DWI signal intensity (SI), and ADCmean were evaluated at MRI after nCRT...
October 15, 2018: European Radiology
https://www.readbyqxmd.com/read/30324275/efficacy-of-neoadjuvant-pertuzumab-in-addition-to-chemotherapy-and-trastuzumab-in-routine-clinical-treatment-of-patients-with-primary-breast-cancer-a-multicentric-analysis
#7
Peter A Fasching, Andreas D Hartkopf, Paul Gass, Lothar Häberle, Leyla Akpolat-Basci, Alexander Hein, Bernhard Volz, Florin-Andrei Taran, Naiba Nabieva, Birgit Pott, Friedrich Overkamp, Hanna Einarson, Peyman Hadji, Hans Tesch, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Wolfgang Janni, Tanja N Fehm, Andreas Schneeweiss, Michael Untch, Dirk Pott, Michael P Lux, Thomas Geyer, Cornelia Liedtke, Harald Seeger, Sarah Wetzig, Arndt Hartmann, Rüdiger Schulz-Wendtland, Erik Belleville, Diethelm Wallwiener, Matthias W Beckmann, Sara Y Brucker, Hans-Christian Kolberg
PURPOSE: Neoadjuvant combination treatment with chemotherapy (CTX), trastuzumab (TZM), and pertuzumab (PTZ) has been shown to result in higher pathological complete response rates (pCR) in comparison with treatment with chemotherapy and trastuzumab (CTX/TZM). This analysis was aimed at real-world validation of these results from prospective randomized trials. METHODS: In a retrospective analysis conducted in the PRAEGNANT network, patients were eligible for inclusion if they had either received neoadjuvant therapy with CTX/TZM or chemotherapy, trastuzumab, and pertuzumab (CTX/TZM/PTZ) and subsequently underwent surgery for their primary breast cancer...
October 15, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/30324273/a-nomogram-to-predict-pathologic-complete-response-pcr-and-the-value-of-tumor-infiltrating-lymphocytes-tils-for-prediction-of-response-to-neoadjuvant-chemotherapy-nac-in-breast-cancer-patients
#8
REVIEW
Hye Won Hwang, Hera Jung, Jiyeon Hyeon, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jong-Han Yu, Se Kyung Lee, Misun Choi, Soo Youn Cho, Eun Yoon Cho
PURPOSE: The value of tumor-infiltrating lymphocytes (TILs) for prediction of pathologic complete response (pCR) in breast cancer (BC) patients treated with neoadjuvant chemotherapy (NAC) has received increasing attention. In human epidermal growth factor receptor 2 (HER2)-positive BC, advances in HER2-targeted therapy have not yet clarified the clinical implications of pre-NAC TILs. Likewise, the prognostic role of TILs for long-term survival is not well established. METHODS: Pre- and post-NAC TIL levels were evaluated in 248 pair-matched pre-NAC biopsy and post-NAC resection samples, and analyzed for predictive and prognostic significance with other clinicopathologic parameters...
October 15, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/30323753/sarcomatoid-variant-of-bladder-carcinoma-a-case-report
#9
Koichi Uemura, Takashi Kawahara, Hiroaki Ishida, Noboru Nakaigawa, Mikiko Tanabe, Masahiro Yao, Hiroji Uemura
A 59-year-old man was referred to our hospital complaining of asymptomatic gross hematuria. Cystoscopy revealed a papillary tumor 8 cm in diameter filling the bladder. The patient underwent transurethral resection of the bladder tumor. The pathological findings revealed the sarcomatoid variant of urothelial carcinoma with a heterologous osteosarcomatous element. He had no metastasis according to our imaging analyses; thus, we planned radical cystectomy after two courses of neoadjuvant chemotherapy (gemcitabine and cisplatin)...
September 2018: Case Reports in Oncology
https://www.readbyqxmd.com/read/30323666/locoregional-recurrence-associated-factors-and-risk-adapted-postmastectomy-radiotherapy-for-breast-cancer-staged-in-ct1-2n0-1-after-neoadjuvant-chemotherapy
#10
Xin Wang, Liming Xu, Zhenzhen Yin, Daquan Wang, Qi Wang, Kunpeng Xu, Jinlin Zhao, Lujun Zhao, Zhiyong Yuan, Ping Wang
Objective: In order to identify risk factors associated with locoregional recurrence (LRR) and assess the role of postmastectomy radiotherapy (PMRT) in early breast cancer (BC), managed with neoadjuvant chemotherapy (NAC) and mastectomy, a retrospective analysis of BC diagnosed with clinical stage T1-2N0-1 was conducted. Patients and methods: A total of 217 patients were included in this analysis. The median age was 50 years (24-72 years). The clinical stage distributions were cT1 in 15 cases, cT2 in 202, cN0 in 53, and cN1 in 161 cases...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/30322514/understanding-the-impact-of-chemotherapy-on-dignity-for-older-people-and-their-partners
#11
Carole Farrell, Catherine Heaven
PURPOSE: Chemotherapy poses challenges for older patients, with potential comorbidities, mobility and functional problems that may adversely affect their dignity. Patients may struggle with side-effects but fail to inform health professionals, impacting on clinical management and unresolved needs/concerns. This study aims to explore the impact of dignity during chemotherapy for older people and partners. METHODS: A qualitative study using semi-structured interviews of patients/partners following chemotherapy for non-metastatic cancer...
October 2018: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://www.readbyqxmd.com/read/30321552/concurrent-radiotherapy-and-panitumumab-after-lymph-node-dissection-and-induction-chemotherapy-for-invasive-bladder-cancer
#12
Elisabeth E Fransen van de Putte, Floris Pos, Barry Doodeman, Bas W G van Rhijn, Elsbeth van der Laan, Petra Nederlof, Michiel S van der Heijden, Jolanda Bloos van der Hulst, Joyce Sanders, Annegien Broeks, J Martijn Kerst, Vincent van der Noort, Simon Horenblas, Andries M Bergman
PURPOSE: In this prospective study we evaluated safety and efficacy of concurrent radiotherapy and panitumumab following neoadjuvant/induction chemotherapy (ICT) and pelvic lymph node dissection (PLND) as a bladder preserving therapy for invasive bladder cancer (BC). MATERIALS & METHODS: Patients with cT1-4N0-2M0 bladder cancer were treated with PLND and 4 cycles of platinum-based ICT, followed by a six-and-half-week schedule of weekly panitumumab (2.5 mg/kg) and concurrent radiotherapy to the bladder (33x2 Gy)(RT/P)...
October 12, 2018: Journal of Urology
https://www.readbyqxmd.com/read/30321230/tissue-microarray-analysis-delineate-potential-prognostic-role-of-annexin-a7-in-prostate-cancer-progression
#13
Ximena Leighton, Alakesh Bera, Ofer Eidelman, Lukas Bubendorf, Tobias Zellweger, Jaideep Banerjee, Edward P Gelmann, Harvey B Pollard, Meera Srivastava
BACKGROUND: Annexin A7 (ANXA7) is a member of the multifunctional calcium or phospholipid-binding annexin gene family. While low levels of ANXA7 are associated with aggressive types of cancer, the clinical impact of ANXA7 in prostate cancer remains unclear. Tissue microarrays (TMA) have revealed several new molecular markers in human tumors. Herein, we have identified the prognostic impact of ANXA7 in a prostate cancer using a tissue microarray containing 637 different specimens. METHODS: The patients were diagnosed with prostate cancer and long-term follow-up information on progression (median 5...
2018: PloS One
https://www.readbyqxmd.com/read/30320451/lncrna-and-mrna-signatures-associated-with-neoadjuvant-chemoradiotherapy-downstaging-effects-in-rectal-cancer
#14
Ning Li, Jing Yu, Aiping Luo, Yuan Tang, Wenyang Liu, Shulian Wang, Yueping Liu, Yongwen Song, Hui Fang, Bo Chen, Shunan Qi, Ningning Lu, Zihao Yu, Yexiong Li, Zhihua Liu, Jing Jin
Radiotherapy plays a crucial role in combined treatment modality in local advanced rectal cancer (LARC). While neoadjuvant chemoradiotherapy responses were variable in LARC patients, so, it is important to identify genes that closely associated with short-term and long-term responses to radiotherapy. In this study, we profiled long noncoding RNAs (lncRNAs) and messenger RNAs (mRNAs) expression values of LARC patients with different neoadjuvant chemoradiotherapy downstaging depth score based on Agilent Arraystar Human LncRNA V3...
October 15, 2018: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/30319327/neoadjuvant-model-as-a-platform-for-research-in-breast-cancer-and-novel-targets-under-development-in-this-field
#15
REVIEW
Santiago Escrivá-de-Romaní, Miriam Arumí, Esther Zamora, Meritxell Bellet
For decades, the neoadjuvant setting has provided a useful scenario for research in breast cancer. Historically, neoadjuvant clinical trials, either hormone therapy-based or chemotherapy-based, have tried to recapitulate the results of their counterpart adjuvant studies, but with smaller patient numbers, more rapid outcomes (clinical response and/or pathologic complete response (pCR)), together with additional biologic information. As for neoadjuvant chemotherapy trials, the increase in pCR rates has been recently accepted as an appropriate surrogate marker to accelerate drug approval in high-risk breast cancer patients...
August 2018: Breast Care
https://www.readbyqxmd.com/read/30319326/standard-neoadjuvant-treatment-in-early-locally-advanced-breast-cancer
#16
REVIEW
Cristina Pernaut, Flora Lopez, Eva Ciruelos
Neoadjuvant treatment allows us to improve surgical results and test new drugs. In recent years, there have been significant advances in the field of neoadjuvant treatment, including hormonal neoadjuvant therapy in luminal tumors, double blockade in HER2-positive tumors, and the use of platinum salts in triple-negative tumors.
August 2018: Breast Care
https://www.readbyqxmd.com/read/30319325/surgical-management-of-breast-cancer-treated-with-neoadjuvant-therapy
#17
REVIEW
Octavi Cordoba, Lourdes Carrillo-Guivernau, Carmen Reyero-Fernández
Neoadjuvant therapy (NAT) allows downstaging in some cases of breast cancer. By consequence, it may enable a more conservative surgical approach or make surgery possible in cases ineligible for surgery before NAT. In this article, we review the evidence and management recommendations for optimal surgical treatment in this setting.
August 2018: Breast Care
https://www.readbyqxmd.com/read/30319324/from-standard-of-care-to-the-neoadjuvant-model-as-an-innovative-platform-for-exploring-promising-combinations-in-breast-cancer
#18
EDITORIAL
Cristina Saura
No abstract text is available yet for this article.
August 2018: Breast Care
https://www.readbyqxmd.com/read/30318451/factors-affecting-local-regrowth-after-watch-and-wait-for-patients-with-a-clinical-complete-response-following-chemoradiotherapy-in-rectal-cancer-intercore-consortium-an-individual-participant-data-meta-analysis
#19
Sami A Chadi, Lee Malcomson, Joie Ensor, Richard D Riley, Carlos A Vaccaro, Gustavo L Rossi, Ian R Daniels, Neil J Smart, Melanie E Osborne, Geerard L Beets, Monique Maas, Danielle S Bitterman, Kevin Du, Simon Gollins, Arthur Sun Myint, Fraser M Smith, Mark P Saunders, Nigel Scott, Sarah T O'Dwyer, Rodrigo Otavio de Castro Araujo, Marcus Valadao, Alberto Lopes, Cheng-Wen Hsiao, Chien-Liang Lai, Radhika K Smith, Emily Carter Paulson, Ane Appelt, Anders Jakobsen, Steven D Wexner, Angelita Habr-Gama, Guilherme Sao Julião, Rodiguo Perez, Andrew G Renehan
BACKGROUND: In patients with rectal cancer who achieve clinical complete response after neoadjuvant chemoradiotherapy, watch and wait is a novel management strategy with potential to avoid major surgery. Study-level meta-analyses have reported wide variation in the proportion of patients with local regrowth. We did an individual participant data meta-analysis to investigate factors affecting occurrence of local regrowth. METHODS: We updated search results of a recent systematic review by searching MEDLINE and Embase from Jan 1, 2016, to May 5, 2017, and used expert knowledge to identify published studies reporting on local regrowth in patients with rectal cancer managed by watch and wait after clinical complete response to neoadjuvant chemoradiotherapy...
October 11, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30318310/neoadjuvant-transcatheter-arterial-chemoembolization-and-systemic-chemotherapy-for-treatment-of-clear-cell-sarcoma-of-the-kidney-in-children
#20
Jin-Hu Wang, Min-Ju Li, Da-Xing Tang, Shan Xu, Jun-Qing Mao, Jia-Bin Cai, Min He, Qiang Shu, Can Lai
BACKGROUND: Clear cell sarcoma of the kidney (CCSK) is a rare and aggressive malignant renal tumor. We describe our experience with neoadjuvant transcatheter arterial chemoembolization (TACE) and systematic chemotherapy for the treatment of advanced CCSK in children. METHODS: Between January 2010 and December 2016, seven patients (3 boys and 4 girls; median 2.2 years) with advanced CCSK received preoperative TACE of renal artery and systemic chemotherapy. The chemoembolic emulsion for TACE consisted of cisplatin, pirarubicin, vindesine, and iodized oil...
October 2, 2018: Journal of Pediatric Surgery
keyword
keyword
168454
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"